3results about How to "Effective way" patented technology

This invention discloses a transgenic recombinant immune cell that specifically targets tumors. The recombinant immune cell comprises a chimeric polypeptide and a chimeric antigen receptor; the chimeric polypeptide includes a first extracellular region, a first transmembrane region, and a first intracellular region with HLA-G protein binding activity, wherein the N-terminus of the first transmembrane region is connected to the C-terminus of the first extracellular region, and the N-terminus of the first intracellular region is connected to the C-terminus of the first transmembrane region; the first transmembrane region includes the transmembrane region of the Notch receptor protein from Xenopus laevis; the antigen-chimeric receptor does not have HLA-G protein binding activity. This recombinant immune cell significantly improves the precise recognition of tumor cells by immune cells, reduces off-target effects of cell therapy, and accurately and effectively distinguishes tumor cells from normal cells, providing an effective target and targeting method for the treatment of broad-spectrum tumors (especially solid tumors).

The application relates to application of L-selenomethionine oligopeptide in preparation of an antitumor drug, and L-selenomethionine oligopeptide (III) is further prepared by using synthesized L-selenomethionine (II). The L-selenomethionine oligopeptide has good antitumor activity, and (II-1) to (II-10) in the application have good inhibitory activity on cervical cancer cells. The results obtained by the application show that the L-selenomethionine oligopeptide has wide application prospects in a drug development system, a new and wider idea is provided for synthesizing and screening the L-selenomethionine oligopeptide, and a more effective way is provided for treating related diseases.

The application discloses a strain for significantly improving HSAF yield under iron limitation and application thereof, and the genetically engineered bacterium is obtained by knocking out or silencing an iron response transcription factor Fur gene of L.enzymogenes OH11, and the nucleotide sequence of the Fur gene is shown as SEQ ID NO.1.Compared with a wild type strain, the mutant strain has no significant difference in growth in an iron deficiency or low-iron culture medium, and the HSAF synthesis capacity is greatly improved.The HSAF yield of the mutant strain in the iron deficiency culture medium reaches 162.34+5.84 mg / L, which is 3.60 times of that of the wild type strain.Therefore, the technical scheme of the application provides a more direct and effective way for improving the HSAF yield of L.enzymogenes OH11 in the iron deficiency or low-iron environment.